COMMUNIQUÉS West-GlobeNewswire

Hyperion DeFi, Anchorage Digital, and HyperLend Together Announce the First Institutional Credit Facility on Hyperliquid
30/09/2026
Institutional Credit Layer on HyperEVM Secured by Collateral in Qualified Custody at a Federally Chartered Bank DALLAS, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “ [...]
HealthEquity Appoints Moody’s CFO Noémie Heuland to Board of Directors
30/09/2026
DRAPER, Utah, Sept. 30, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the largest independent health savings account (HSA) custodian by account volume and a leader in [...]
Highlight Therapeutics Presents Positive Phase 2b Topline Results of Intralesional BO-112 in Localized Basal Cell Carcinoma as a Late-Breaker at EADV
30/09/2026
Primary composite endpoint met: 61% of patients achieved visual and pathological response across all treated lesions. Complete clinical and pathological response in 56% of high-risk head & neck patients and 62% of [...]
OneMedNet Signs Seven Figure Multiyear Agreement to Power a Partner Sold Derivative Data Solution
30/09/2026
First party, direct-from-source Real World Data will feed the Company’s tenth channel partner’s AI models and a licensable derivative dataset that partner will sell MINNEAPOLIS, Sept. 30, 2026 (GLOBE NEWSWIRE) -- [...]
Silo Pharma’s QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility
30/09/2026
Addition of NVIDIA Nemotron models and Hermes runtime expands customer choice across both AI models and agent software SARASOTA, FLA., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the [...]
Avaí Bio and Austrianova Successfully Encapsulate GMP-Quality Klotho-Producing Cells, Achieve Robust Klotho Secretion
30/09/2026
LAS VEGAS, NEVADA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotech developing transformative cell-based therapies for diabetes, age-related disorders, and [...]
AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
30/09/2026
Company highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestones Access it here OCALA, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- AIM [...]
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
30/09/2026
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute [...]
Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026
30/09/2026
In a year-long functional magnetic resonance imaging (fMRI) study - a non-invasive method to measure brain activity during specific tasks - CagriSema changed how the brain reacted to tempting, high-calorie foods in [...]
Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance
30/09/2026
FDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning the Company for potential initial U.S. clearance of its standalone sensing [...]
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
30/09/2026
Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with recently disclosed evidence of persistent local immune remodeling, these findings provide [...]
Project MEND Uses SteraMist to Safely Disinfect Medical Equipment for Reuse
30/09/2026
FREDERICK, Md., Sept. 30, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced Project MEND , a San [...]
Decoy Therapeutics to Present at The Small Cap Showcase
30/09/2026
CEO Rick Pierce to deliver an investor presentation on Thursday, October 1 in New York CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc . (NASDAQ: DCOY), a biotechnology company pioneering [...]
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
30/09/2026
Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept. 30, 2026 (GLOBE NEWSWIRE [...]
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
30/09/2026
Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- [...]
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
30/09/2026
WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced [...]
Ocugen to Participate in Upcoming Scientific Conferences
30/09/2026
MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company [...]
AnaCardio raises €62.5 million Series B financing to advance transformational novel therapy in heart failure towards Phase 3 readiness
30/09/2026
Financing co-led by Novo Holdings and the Ljungström family office, with participation from the originator Helsinn, existing investors Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie, LLD Nybohov Invest AB [...]
R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia
30/09/2026
Samsara BioCapital, a leading biotech investor active across private and public markets, joins global investor syndicate Funds will be used to advance AP306, a first-in-class pan phosphate transporter inhibitor in [...]

Pages